• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    111 Inc. Expands National Supply Chain Network with New Fulfillment Centers across South and Central China

    10/10/24 6:02:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $YI alert in real time by email

    SHANGHAI, Oct. 10, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that new fulfillment centers in South and Central China began operations in Guangzhou, Guangdong Province, and Wuhan, Hubei Province, respectively. These strategic expansions mark a significant step forward in enhancing its national supply chain network, increasing efficiency and speed to better meet growing market demand.

    The two new centers expand the scale and capabilities of 111's existing operations in the South and Central China regions. With innovation and technological upgrades, the centers enable faster and more efficient operations. The additional fulfillment centers bring the total number in 111 operations to 13 across China, ensuring a more robust and agile warehousing and distribution network nationwide.

    By utilizing a newly designed operational model, these centers will significantly reduce operating costs while expanding warehousing capacity with higher cost efficiency. This will also improve the efficiency of operations and deliveries in the South and Central China markets, with most deliveries now being fulfilled within 24 hours. With a stronger national supply chain network, 111 is well positioned to deliver to over 300 major cities nationwide within 24 hours and cover the entire nation within 72 hours.

    Additionally, 111's nationwide logistics network, "Kunpeng," continues to improve operational efficiency by streamlining connections between fulfillment centers through its digitalized long-haul and last-mile distribution models. As a result, delivery costs have been slashed by 15%, and delivery damage rates have been cut by 55%. These improvements address key industry challenges, such as slow delivery times, high damage rates and inefficient quality control processes, while providing seamless logistics services to partners across the supply chain.

    111's continuous technological innovation empowers its smart supply chain management systems as core drivers of success. These systems, among the most complex in 111's digital suite, support the Company's nationwide supply chain operations and include over 30 self-developed technologies ranging from procurement and inventory management to distribution and pricing.

    The innovative supply chain and logistics network, combined with smart management systems, underpins 111's nationwide virtual pharmacy network, a key outcome from its industrial internet strategy. This virtual network currently serves approximately 470,000 pharmacies and boasts partnerships with over 500 global pharmaceutical companies and 4,500 distributors, underscoring the Company's growing influence in the healthcare and pharmaceutical industries.

    Mr. Junling Liu, Co-Founder, Chairman, and Chief Executive Officer of 111, commented, "The opening of our new fulfillment centers in South and Central China is critical in strengthening our supply chain and delivering exceptional service to our customers. By integrating cutting-edge technology and operational innovation, we are now able to further enhance our delivery speed, reduce costs, and improve overall efficiency. These centers not only reinforce our market presence in key regions but also support our vision of becoming the go-to platform for pharmaceutical products with the best selection as well as prices across China. As we continue to scale up, we remain focused on driving operational excellence and creating long-term value for our partners, customers, and shareholders."

    Forward-Looking Statements

    This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    About 111, Inc.

    111, Inc. (NASDAQ:YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.

    For more information on 111, please visit: http://ir.111.com.cn/. 

    Cision View original content:https://www.prnewswire.com/news-releases/111-inc-expands-national-supply-chain-network-with-new-fulfillment-centers-across-south-and-central-china-302272803.html

    SOURCE 111, Inc.

    Get the next $YI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YI
    SEC Filings

    View All

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    12/17/25 6:13:16 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    9/17/25 6:09:10 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form 20-F/A filed by 111 Inc.

    20-F/A - 111, Inc. (0001738906) (Filer)

    8/29/25 6:03:53 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Teo Nee Chuan

    3 - 111, Inc. (0001738906) (Issuer)

    3/20/26 6:31:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 3 filed by new insider Luo Jun Justin

    3 - 111, Inc. (0001738906) (Issuer)

    3/20/26 6:30:20 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 3 filed by new insider Sun Jian David

    3 - 111, Inc. (0001738906) (Issuer)

    3/20/26 6:28:03 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on 111, Inc. with a new price target

    Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00

    4/15/21 6:56:01 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

    Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)

    12/17/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in

    9/17/25 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces First Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses

    6/19/25 3:03:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Leadership Updates

    Live Leadership Updates

    View All

    111, Inc. Announces Change to Board of Directors

    SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr

    11/4/24 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 Announces Appointment of New Auditor

    SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar

    7/19/24 8:45:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")

    9/23/22 12:30:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Financials

    Live finance-specific insights

    View All

    111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four

    3/20/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

    SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q

    2/20/25 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

    Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same

    11/27/24 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    2/27/24 8:02:40 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    7/17/23 9:00:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    10/31/22 7:57:04 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples